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Preliminary results were presented at the 58th Annual Meeting of the American 
Society of Hematology, held on December 3 – 6, 2016, in San Diego, US. 
ABSTRACT  
JAK2 constitutive activation/overexpression is common in classical Hodgkin 
lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing 
JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in 
HL.  
This Phase II study assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 
inhibitor, in relapsed/refractory Hodgkin lymphoma patients. The primary objective 
was overall response rate according to IHP 2007 criteria. 
Thirty-three advanced patients (median prior lines: 5; refractory: 82%) were included; 
nine (27.3%) received at least 6 cycles of ruxolitinib and six (18.2%) > 6 cycles 
therapy. The overall response rate after 6 cycles was 3/32 (9.4%) patients, all partial 
responders, with transient stable disease in 11/32. Best overall response rate was 
6/32 (18.8%). Rapid alleviation of B-symptoms was commonly noted. Median 
response duration was 7.7 months, median progression-free survival 3.5 months 
(95%CI: 1.9-4.6), and median overall survival 27.1 months (95%CI: 14.4-27.1). Forty 
adverse events were reported in 14/33 patients (42.4%); one led to treatment 
discontinuation; 87.5% recovered without sequelae. Twenty-five were of > Grade3. 
The latter consisted mostly of anemia (n=11) all considered related to ruxolitinib. 
Other main causes of > Grade3 adverse events included lymphopenia and infections. 
Of note, there was no Grade4 neutropenia or thrombocytopenia observed.  
Ruxolitinib shows signs of activity, though short-lived, beyond simple anti-
inflammation. Its limited toxicity suggests the potential of being combined with other 
therapeutic modalities. ClinicalTrials.gov: NCT01877005 
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INTRODUCTION 
Hodgkin's lymphoma (HL) is regarded as a curable malignancy in most cases, yet 
treatment failure still occurs in about 10% of early-stage disease1. In advanced-stage 
disease, up to 10% of cases do not reach complete remission (CR) and are thus 
considered primary refractory HL2, while 20-30% of primary responders eventually 
relapse following first-line treatment3. 
For most patients with relapsed or refractory HL (R/R HL), the standard of care 
consists of high-dose salvage chemotherapy followed by autologous stem-cell 
transplantation (ASCT). For patients who experience R/R HL within 1 year of ASCT, 
the prognosis proves extremely poor, with a median survival time of 1.2 years4. For 
patients failing all classical approaches, new strategies including checkpoint inhibitors 
targeting PD-1 or antibody-drug conjugates targeting CD30 have become part of our 
therapeutic armamentarium against R/R HL5-8. However, patients with multiple 
relapses or who develop refractory disease remain in medical need, especially those 
failing brentuximab vedotin (BV) and PD-1 blockers   
Classical HL is characterized by the presence of Hodgkin and Reed-Sternberg 
(HRS) cells and their variants9. HRS cells were demonstrated to shape their 
environment by secreting immunosuppressive cytokines and chemokines10. With this 
in mind, the Janus kinase (JAK) STAT pathway appears to be a relevant cytokine-
induced signal transduction pathway shown to directly transfer signals from cell 
surface cytokine receptors to the cell nucleus. Given that enhanced JAK-mediated 
signaling was demonstrated in a significant number of HL patients11, this signaling 
pathway has become a focus for developing novel therapeutic agents for the 
disease. Van Roosbroeck et al. reported JAK2 to be translocated in several cases of 
HL12, with JAK inhibition shown to decrease the proliferation of cell lines. Whereas 
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such translocations are relatively rare, 9p24.1 genomic amplification including the 
JAK2 locus appears common in HL, along with increased protein expression and 
activity, resulting in the constitutive activation of STAT6, an essential messenger of 
tumor cell growth 13-15. In corollar, JAK 1/2 inhibition may be suitable to target the 
constitutive activation caused by either JAK2 translocation or JAK2 amplification and 
to impact the reactive microenvironment which contributes to HL growth via aberrant 
cytokine production16.  
Ruxolitinib is the first potent, selective, and oral inhibitor of JAK1/2 being 
developed for clinical use17. Its major effects include inhibition of proliferation, 
induction of apoptosis, and reduction in cytokine plasma levels, all mediated by the 
drug's ability to inhibit JAKs' capability to phosphorylate signal transducer and 
activator of transcription (STAT)18. In myelofibrosis, ruxolitinib exhibited durable 
efficacy in reducing splenomegaly and alleviating constitutional symptoms, and 
patients exhibited weight gain and improvement in their general physical condition19. 
The dose-limiting toxicity was thrombocytopenia, fairly-well managed via dose 
reduction or brief treatment interruption. In the present phase II study, we sought to 
investigate the safety and efficacy of ruxolitinib in patients with R/R HL. Exploratory 
biomarker analyses pertaining to plasma cytokine profiles and aberrations of JAK2 
were also carried out.  
 
METHODS 
Patient Eligibility 
Patients aged 18 years or older with a diagnosis of R/R HL were eligible for entering 
the trial after having receiving at least one prior therapy, and for whom no treatment 
with proven efficacy was available, provided that they had measurable nodal disease 
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at baseline (≥1 cm in the longest transverse diameter, clearly measurable in at least 
two perpendicular dimensions) on computed tomography (CT) or magnetic 
resonance imaging (MRI), as well as an Eastern Cooperative Oncology Group 
(ECOG) performance score of ≤3. Additional inclusion criteria were absolute 
neutrophil count (ANC) ≥1.0 x 109/L, platelet count ≥75 x 109/L, serum creatinine ≤1.5 
x upper limit of normal (ULN), serum bilirubin ≤1.5 x ULN, and ALT and AST levels 
≤2.5 x ULN or ≤5.0 x ULN in the event the transaminase enhancement was due to 
HL-related liver disease. Pregnant or lactating patients were not allowed to be 
included into the trial, and men and women of childbearing potential had to agree to 
employ an adequate contraceptive method during the study treatment. Patients were 
permitted to have an undefined number of prior therapy lines, and prior allogeneic 
SCT was likewise allowed provided that patients had not received any 
immunosuppressive therapy within 90 days prior to starting the screening 
procedures. Patients were required to display a life expectancy of ≥3 months.  
 
Study Design and Treatment 
This multicenter, open-label, Phase II study (HIJAK, NCT01877005) was conducted 
at 10 LYSA centers in France and Belgium, with patients recruited from July 2013 
through December 2014. Its primary efficacy endpoint was overall response rate 
(ORR), defined as the proportion of patients with complete response (CR) or partial 
response (PR), at 6 months of treatment by investigator assessment based on the 
revised response criteria for malignant lymphoma (Cheson 2007)20. Secondary 
objectives included B symptoms relief, best ORR (occurring at any time during 
study), duration of response (DOR), progression-free survival (PFS), overall survival 
(OS), as well as the incidence and severity of adverse events (AE).  
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The study was carried out in line with the ethical principles of the Helsinki Declaration 
and in compliance with the International Conference on Harmonization Guideline for 
Good Clinical Practice. The protocol was approved by the institutional review board 
of each study site and written informed consent was obtained from all patients. 
Starting dose of ruxolitinib was 20mg given twice daily during six 28-day cycles for 
the induction period, if platelet count >200 x 109/L. Ruxolitinib dose was diminished to 
15mg twice daily for patients with platelet counts between 75 and 200 x 109/L. 
Patients who achieved at least stable disease (SD) at the end of cycle 6 and for 
whom, according to the Investigator's opinion, a clinical benefit was observed were 
eligible for continuing ruxolitinib (15mg or 20mg), defined as a “maintenance”. 
Treatment could be pursued for up to 2 years or until progressive disease (PD), 
intolerability, or as long as the investigator sought that there was clinical benefit. 
Study drug administration could be stopped for any Grade ≥3 non-hematological 
toxicity, with the exception of deep venous thrombosis and alopecia. Following event 
resolution to Grade <1, ruxolitinib could be resumed, with a 5 mg dose reduction and 
a maximum delay of 4 weeks. Mandatory dose decreases or interruptions for 
hematological toxicity as well as rules for permanent discontinuation are detailled in 
Supplementary Appendixes. Growth factors were allowed as per ASCO guidelines 
and infectious prophylaxis as per the guidelines of Heine et al 21. 
 
Study Assessments 
Baseline assessments comprised documentation of disease-related symptoms, 
physical examination, laboratory tests, and imaging studies of the neck, chest, 
abdomen, and pelvis, using CT or magnetic resonance imaging (MRI). Biopsy prior to 
inclusion was recommended, though not mandatory. Tumors were measured at 
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baseline, at the end of every two cycles, and following the six-cycle induction, as well 
as during maintenance therapy. Given the exploratory nature of the study, there was 
no centralized review of CT response. However, PET of the responders were all 
centrally reviewed by a nuclear physician (ASC) to confirm partial or complete 
metabolic response based on Deauville five-point scale. The evaluable set for 
efficacy was restricted to patients who had received at least 28 days of the study 
drugs.  
Safety was monitored up to 1month post-treatment. AEs were summarized by means 
of the Medical Dictionary for Regulatory Activities, and graded using the National 
Cancer Institute’s (NCI) Common Terminology for Adverse Events, Version 3.0. 
Laboratory abnormalities were assessed according to the NCI-CTCAE Version 4.0. 
Only Grade 3 or 4 toxicities and Grade 2 infections were to be reported. All patients 
were included in the toxicity analysis. 
 
Exploratory Biomarker Analysis 
Blood samples (5mL) were taken at baseline prior to drug administration and on 
Cycle 2, Day 1, for the measurement of 27 cytokines related to the immune system 
using bead-based immunoassays (L.K.). Analysis of JAK2 gains, amplifications, and 
gene rearrangements was also performed (H.A.P.) using fluorescent in situ 
hybridization (FISH) with 2 tri-color sets of probes associating JAK2/9p24 break-apart 
probes with a control centromeric probe (CEP9/9q21): the already prepared probes 
from Empire genomics on one hand, and the association of the JAK2 B/A probe from 
Kreatech with the CEP9 probe from Vysis on the other hand. The CD274/PDL1 and 
PDCD1LG2/PDL2 loci at 9p24 were studied with home-made prepared bacterial 
artificial chromosome (BACs) probes purchased from the Chori BACPAC Resources 
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Center (Oakland). Extraction, labelling and hybridization were performed on paraffin 
embedded tissue, as previously reported.22  
 
Statistical Methods 
The sample size in this Phase II study was calculated using an exact single-stage 
Phase II design23, along with the following hypothesis. A two-stage design with 
interim analysis for activity or toxicity was not planned given the very advanced stage 
of the patient, with relative paucity of alternative options, and the potential toxicity of 
ruxolitinib that was expected to be in the low range, based on myelofibrosis data. The 
treatment was considered ineffective if the ORR was ≤15%, and effective if ORR 
≥35%. Under the assumption of an alpha first-order risk error set at 5% and beta at 
20% with one-sided test, it was deemed necessary to include a total of 28 evaluable 
patients with a cut-off number of eight. If at least eight patients displayed an ORR, 
the hypothesis ORR ≤15% was rejected with a target error rate and an actual error 
rate of both 0.05. If seven or less patients displayed an ORR, the hypothesis ORR 
≥35% was rejected with a target error rate of 0.2 and an actual error rate of 0.187. 
The ORR estimate and its 90% confidence intervals (CI) were calculated for all 
patients who completed at least one study drug cycle.  
The Kaplan-Meier method was employed to estimate the median value and its 95% 
CI for TTR, DOR, PFS, and OS. The safety set comprised all patients who received 
at least one study drug. All statistical analyses were performed using the SAS 
software, Version 9.2. P-values <0.05 were considered statistically significant. All 
available data was included in data listings and tabulations, with no imputations of 
values for missing data conducted. An interim analysis was neither planned nor 
performed.  
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RESULTS 
Patient Disposition and Characteristics 
Patient characteristics are listed in Table 1. From July 2013 to December 2014, a 
total of 33 patients with R/R HL were recruited. Median age was 37 years (range, 19-
80), patients mostly had advanced HL (Stage III/IV), and were heavily pretreated, 
with a median number of five prior regimens including ASCT (54%), allo-SCT(15%), 
and BV (82%). Of the patients, 27 (82%) had refractory disease HL. Among the 33 
patients, 22 had biopsy-confirmed relapse of HL. Among the six patients displaying 
response, a biopsy at relapse was performed in five of them 8 days, 12 days, 6 
weeks (n=2) and 14 months prior to inclusion. 
 
Patient Drug Exposure 
The median number of ruxolitinib cycles administered was 4, ranging from 1 to 12 
(Table 2). Among the patient population, nine received all planned six cycles, of 
whom six continued on maintenance therapy with ruxolitinib. The remainder 
discontinued ruxolitinib therapy, for the most part due to PD, and owing to AEs in one 
patient.  
 
Response and outcome 
The patient disposition is illustrated in Fig. 1. Among the 33 HL patients included into 
the trial, one patient did not complete the first cycle owing to PD and was thus not 
included in the efficacy analysis. ORR at the end of the ruxolitinib induction period (6 
months) was 3/32 (9.4%; 90% CI: 2.6-22.5%), all being PRs. Best ORR at any time 
throughout induction was 6/32 (18.8%; 95% CI: 7.2-36.4%), all PRs. A detailled 
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analysis of responders characteristics is provided in Table 3. Fig. 2 and 3 illustrate 
metabolic evolution in 2 patients. Interestingly, UPN 611001, who had achieved PR 
after 6 cycles, eventually converted into CR during follow-up, beyond the six cycles. 
Achievement of complete metabolic response was confirmed by central review. At 
the time of writing, two patients (UPN 611001 and 881001) are still taking ruxolitinib. 
Fig. 4 displays change in target tumour measurement in individual patients. If any, 
best reduction at any time throughout treatment was taken. 
In addition, during 6-month induction, transient stable disease was recorded in 11 
patients, though of limited duration. Overall, the disease control rate (thus including 
SD with CR and PR) was 53.1% (n=17/32), (95%CI : 34.7-70.9%] of a median 
duration of 1.9 month. 
The alleviating effect on systemic symptoms, such as pruritus, fever, and sweating, 
was noteworthy, starting within the first month of drug administration and commonly 
lasting. The impact was the most remarkable on the control of pruritus, which 
affected 35.5% of patients prior to initiating therapy but only 6.6% after the first 
ruxolitinib cycle. Sweating, which was present in 32.2% of the patients at inclusion, 
was reduced to 20% after one cycle. Fever was abolished in 3/4 patients presenting 
this symptom at inclusion. 
The median follow-up was 17.5 months. As illustrated in Fig. 5, median PFS was 3.5 
months (95% CI: 1.9-4.6). Median duration of response was 7.7 months (95% CI: 
1.8-NA) for the six patients who eventually achieved response (not shown). Overall, 
30 patients displayed PD, with 97% at the initial site and/or 60% at new sites. 
Following ruxolitinib discontinuation, 25 (83.3%) patients were given further 
treatments, consisting of chemotherapy in 19, and immunotherapy in nine, the latter 
comprising rituximab in four, BV in three, and nivolumab in two. Transplantation was 
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eventually carried out in five patients, consisting of allogenic SCT in four and ASCT in 
the remaining one. Among the 25 patients prescribed further therapy, the CR and PR 
rates observed were 10 and 15%, respectively. Overall, twelve patients died on 
account of lymphoma progression (83.3%), toxicity of other treatments (8.3%), or 
other reasons (8.3%). Median OS was 27.1 months (95% CI: 14.4-27.1). 
 
Safety 
All patients enrolled into the study received at least one dose of study medication and 
were thus included into the safety set. A total of 40 AEs was observed in 14/33 
patients (42.4%). In 6 patients, AEs were related to ruxolitinib. In eight of them, AEs 
were of > grade3 (Table 4A). Among the 40 AEs recorded, 30 (75%) occurred during 
induction, 35 (87.5%) recovered without sequelae, 18 (45%) were related to 
ruxolitinib. There was no drug-related death recorded, one AE resulted in permanent 
drug discontinuation, while 87.5% of AEs recovered without sequelae. Characteristics 
and grade of AEs by system organ class and preferred terms are displayed in Table 
4B. Twenty-five (62.5%) were of > Grade3. The latter consisted mostly of anemia 
(n=11) all considered related to ruxolitinib. Other main causes of > Grade3 AE 
included lymphopenia (n=4), infections (n=3) and miscellaneous causes. Of note, 
there was no Grade4 neutropenia or thrombocytopenia observed.  
Eight serious AEs (SAEs) were reported in four patients, either during induction 
(n=5), maintenance (n=1) or after end of treatment (n=2). These SAEs consisted of 
infection in three patients, namely device-related sepsis, gastroenteritis, and lung 
infection. The other SAEs were anemia, diarrhea, subdural hematoma, bone pain, 
and pulmonary embolism. Two SAEs (anemia, lung infection) were deemed drug-
related and six were considered Grade ≥3: infection (n= 3), anemia, subdural 
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hematoma, and pulmonary embolism. Of the eight SAEs, six recovered without 
sequelae, while device-related sepsis and pulmonary embolism, observed in the 
same patient, persisted until the patient died owing to PD and were thus not 
considered as the cause of death. Among the 33 patients, one second primary 
malignancy was observed (colic adenocarcinoma in 80-year old male patient). 
 
Biomarker analysis 
Using bead-based immunoassays, plasma levels of 27 cytokines related to the 
immune system were measured at baseline and after cycle 1. At baseline, there was 
no difference in cytokine levels between responders and non-responders, as defined 
by Cheson 2007 criteria. In responders, the only cytokine that significantly decreased 
was CX-CL10 (P.01). In patients presenting with pruritus (n=11), PDGF-BB 
(Supplemental Appendixes), IL-5, IL-10, IL-12, IL-13, IL-17, eotaxin, FGF basic, 
MIP1b, rantes, and VEGF were significantly increased. In the latter patients, 
ruxolitinib treatment significantly decreased PDGF-BB, IL-10, IL-12, IL-13, IL-17, FGF 
basic and VEGF. Among the patients who were analyzable for JAK2 amplification in 
HRS cells (n=12), polysomy (suggesting hyperdiploidy) was detected in all of them, 
and specific JAK2 amplification in only one. The latter patient achieved PR by CT-
scan criteria and also PET-scan response lasting 4 months. It is noteworthy that the 
PDL1 and PDL2 loci (which are in the vicinity of the JAK2 locus at 9p24) analysed by 
FISH with BAC probes showed the same pattern of gains as for the JAK2 locus. 
 
DISCUSSION 
JAK/STAT activation, driven by an aberrant network of cytokines and chemokines in 
the HL microenvironment, is critical for the proliferation and survival of neoplastic 
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HRS cells24,25. JAK/STAT pathway also plays a role in immune evasion by HL cells 
via secretion of chemokines leading to Th2 homing or via the regulation of PD-L1/L2 
expression, which confer immune privilege to HRS cells. Chromosome 9p24.1/PD-
L1/PD-L2 alterations increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, 
and their further induction through JAK/STAT signaling26-28. This complex crosstalk 
between malignant HRS cells and the reactive microenvironment could be targeted to 
overcome chemoresistance. Based on this rationale, we explored JAK 1/2 inhibition 
in a phase II study of fixed dose ruxolitinib in advanced HL patients before the onset 
of the PD-1 blockers era. With 9.4% ORR at the end of the 6-month induction, this 
study did not reach its primary efficacy goal. Still, when including transient responses 
seen before the 6-month evaluation, ORR was 18.8% in some heavily pretreated 
patients, most of whom where refractory and had failed treatment with BV. These 
responses were sometimes durable (median=7.7 months). Some other patients had 
disease control, but with uncertain clinical benefit. A notable finding to be highlighted 
was the B symptoms and pruritus relief, which was quick and long-lasting, resulting in 
a number of patients being reluctant to discontinue the compound, even despite PD. 
Thus, the latter effect should not be interpreted as a proven surrogate of anti-
lymphoma activity. 
Despite mitigated, these results tend to support the concept of JAK1/2 
inhibition as a potential therapeutical mean in HL. There is presently only scarce data 
available on ruxolitinib use in the HL indication. In a preliminary report of an ongoing 
study, Kim et al showed rapid achievement of disease control (1CR, 5PR, 1SD) out 
of 13 advanced HL patients treated with ruxolitinib at 20 mg bid.29 Younes et al 
reported changes in tumour measurements in HL patients treated in a phase I study 
by SB1518, an inhibitor of JAK2 and FLT-3.30 In vitro, AZD1480, an inhibitor of JAK1 
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and JAK2 kinases, could regulate proliferation in HL cell lines27. The multikinase 
lestaurtinib also showed growth inhibition and apoptotic increment in HL cell lines and 
HL cells from lymph nodes31. Finally, a clinical grade JAK2 inhibitor fedratinib 
inhibited cHL cell lines proliferation in a JAK2 copy number-dependent manner 
implying decreased phosphorylation of STATs and expression of downstream targets 
including PD-L1 showing immunomodulation by JAK inhibitors32. 
If JAK2 is actually an appropriate target, questions arise as to why the study 
outcome was not more convincing. Could the drug's limited activity be attributed to 
insufficient dosage? Given that we observed unambiguous cytokine profile changes 
and frequent B symptoms improvements, it would seem that the dosage of 2x20mg 
was appropriate, a dosage at which target inhibition occurs in myelofibrosis33. 
Another factor possibly influencing the outcome was the stage of our patients, 
represented by the high percentage of refractoriness. At this late stage, the genetic 
changes would be so complex that selective inhibition of JAKs is insufficient in cells 
dependent to other signaling pathways to promote their survival, thus further curbing 
the study's potential. It is known that genomic aberrations, such as chromosome 
breakpoints, are more numerous in HL later clinical stages34. Resistance 
mechanisms to JAK/STAT inhibition have been reported such as a feedback loop of 
paradoxically activated extracellular signal-regulated kinases 1 and 2 (ERK1/2)27. 
Aberrations of the 9p24.1 amplicon, which contains the JAK2 gene, are more 
frequent with advanced disease28. Surprisingly, in our patients, JAK2 amplification 
was seen at a much lower incidence, suggesting a lower proportion of patients 
harboring the target of ruxolitinib, but this should be taken with caution since not all 
patients could be analyzed. It remains that our panel maybe qualified for Jak2 target 
on a limited extent.  
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With respect to safety, ruxolitinib was by and large well-tolerated, with no drug-
related mortality reported. The most prominent toxicities included drug-related 
anemia and manageable infectious events with no specific pattern. The relative lack 
of hematological toxicity suggests that combination with genotoxic compounds could 
be feasible. For patients having discontinued ruxolitinib therapy, a switch to 
chemotherapy and/or immunotherapy was feasible, suggesting that the compound 
does not jeopardize further treatment. 
The question now remains as to how this compound can best be utilized in the 
future. The exploratory nature of our study does not allow identifying best candidates 
on the basis of the clinical stage or biomarkers results. The cytokine profile displays 
changes in patients with pruritus, but the latter are not correlated with clinical 
response. JAK2 status could be explored in a minority of patient, though the only 
patient with JAK2 amplification achieved a response. It will be important to focus on 
biomarkers results in ongoing studies of JAK inhibition in HL. Given its limited 
benefits as monotherapy, combination may possibly enhance its therapeutic 
potential. Ruxolitinib, which has no overlapping toxicity with chemotherapy, has been 
combined with hypomethylating agents, lenalidomide, and even intensive 
chemotherapy.35-38 In vitro data have shown that ruxolitinib could restore sensitivity of 
cisplatin-resistant cell lines with higher Jak2 expression39. Interestingly, the 
combination of BV with ruxolitinib resulted in additive and synergistic killing in a 
xenograft mouse model of HL through a mechanism involving mitochondrial control of 
apoptosis40. Another means to boost ruxolitinib’s potential would be the combination 
with agents blocking other signaling pathways. Interestingly, the combination of 
ruxolitinib with a Bcl2/Bcl-xL inhibitor displayed dramatic synergy in an adult T-cell 
leukemia cell line via a mechanism implying BAX activation41. Finally, the effect of 
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combining chemical JAK blockade and anti-PD1/L1 strategy should be analyzed in 
HL, keeping in mind, however, that a potential antagonism may be encountered due 
to these two drugs acting on the same target, given that PD1-L1 expression is 
dependent on JAK2 activity.  
In conclusion, based on a strong biological rationale for clinical evaluation of 
JAK2 blockade in HL, we initiated a phase II study of ruxolitinib in R/R HL patients. 
The study failed to fulfill the efficacy criteria for further development of the drug as 
monotherapy. Nonetheless, ruxolitinib showed hints of activity that surpasses solely 
anti-inflammatory activity in very advanced patients. This may suggest that further 
improvements will come from a more complete inhibition of signaling pathways 
implied in HRS cell survival or from combination with chemotherapy, such as BV. 
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TABLES 
Table 1 Demographics and patient characteristics 
 
Demographics and patient characteristics All patients N = 33 
Gender, n (%) 
Male 
Female 
 
21 (63.6%) 
12 (36.4%) 
Age in years, median (range) 37.0 (19.0-80.0) 
ECOG 
0 
1 
2 
3 
 
11 (33.3%) 
15 (45.5%) 
5 (15.2%) 
2 (6.1%) 
Ann Arbor stage 
I 
II 
III 
IV 
 
1 (3.0%) 
7 (21.2%) 
3 (9.1%) 
22 (66.7%) 
B symptoms 
Yes 
No 
 
16 (48.5%) 
17 (51.5%) 
Extranodal involvement 
Bone 
Liver 
Lung 
Soft tissues 
 
13 (39.4%) 
6 (18.2%) 
12 (36.4%) 
4 (12.1%) 
Time since initial diagnosis in months, median (range) 55.4 (8.7 – 216.1) 
Prior therapies 
Prior lines, median (range) 
Chemotherapy 
Radiotherapy 
Brentuximab vedotin 
ASCT 
Allogeneic transplantation 
Interval since last treatment in months, median 
(range) 
 
5 (1 – 16) 
33 (100%) 
18 (54.5%) 
27 (82%) 
18 (54.5%) 
5 (15.2%) 
 
6 (1.1 – 75.0) 
Disease status at inclusion 
Relapse 
Refractory 
 
6 
27 (81.8%) 
ASCT: autologous stem cell transplantation; ECOG: Eastern Cooperative Oncology Group. 
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Table 2 Treatment exposure and modifications 
 
Treatment exposure and modifications All patients N = 33 
Cycles given, number, median (range) 
Received full induction (6 cycles), % 
Received maintenance (> 6 cycles), % 
4 (1-22) 
9 (27.3%) 
6 (18.2%) 
Percentage of planned dose
1 
<75% 
(75%-90%) 
(90%-110%) 
(110%-125%) 
 
3 (9.1%) 
4 (12.1%) 
25 (75.8%) 
1 (3.0%) 
Dose modification 
Yes 
Type of modification
2 
Dose reduction 
Dose interruption 
Dose increase 
Number of interrupted days interruption if any, 
median (range) 
 
20 (60.6%) 
 
2 (10.0%) 
18 (90.0%) 
3 (15.0%) 
4 (1 – 28) 
1
Defined as follows: (total number of tablets taken/total expected number of tablets) *100, taking into 
account protocol-defined dose reduction.  
2
The total sum of the percentages for the type and the reasons of modification may be greater than 
100.0% as a patient may specify several types of modification and reasons for treatment modification 
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Table 3 Characteristics of responders (best response achieved during 6-month 
ruxolitinib induction) 
UPN Prior treatment 
Extranodal 
involvement 
Response 
(Cheson 2007) 
N  Type 
611001 9 
ABVD, BEACOPP, MINE, 
IGEV, GVD, CAELYX, GVD, 
RT, BV 
Liver PR*
,1 
211004 8 
ABVD, RT, IVA, 
transplantation, MINE, 
GVD, BV, ASHAP 
Breast PR 
601001 5 
BEACOPP, DHAP, IGEV, 
transplantation-RT, BV 
Liver, bone, 
lung 
PR 
601004 5 ABVD, DHAP, RT, RT, BV None PR 
641001 1 ABVD
2 
None PR 
881001 5 
ABVD, transplantation, 
MINE, BV, GEMOX 
Lung PR
1 
*Patient eventually achieved CR during maintenance 
1
Patients still under treatment by ruxolitinib at the time of writing ; 
2
Patient with 
morbid obesity not eligible for standard approaches with chemo/immunotherapy. 
UPN, unique patient number ; RT, radiotherapy ; BV, brentuximab vedotin 
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Table 4 Treatment-emergent adverse events (AEs) 
A. Patients with AE (N = 33) 
Treatment-emergent adverse events
1 
All patients N = 33 
Patients with > 1 AEs 
N AE/patient, median (range) 
N patients with AE > grade 3 
14 (42.4%) 
2 (1-11) 
8 (24.2%) 
Patients with AE related to ruxolitinib 6 (18.2%) 
Patients with AE leading to drug discontinuation 1 (3%) 
Patients with AE leading to death 0 (0%) 
1
Total number of AE, 40 
 
B. Characteristics of AEs (N = 40) by system organ class and preferred terms 
AE, n (%) Any grade Grade 2 Grades > 3 
Any AE 40 15  25 
Infections and infestations 13 10 3
1 
Anemia 11 0 11 
Lymphopenia 4 0 4 
Thrombocytopenia  2 0 2 
Weight decreased 1 0 1 
Respiratory and thoracic 
disorders 
3 2 1 
Diarrhoea 1 1 0 
Infuenza-like illness 1 1 0 
Subdural hematoma 1 0 1 
Bone pain 1 1 0 
Epilepsy 2 0 2 
1
Implantable device infection, gastro-enteritis, lung infection 
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FIGURE LEGENDS 
Fig. 1 Patient disposition. 
*N months on maintenance therapy: 4, 6, 6, 21, 16, 22;  
 PD: progressive disease. 
 
 
Fig. 2 Response after ruxolitinib. 
Illustrative patient (UPN 601004). (A) PET-CT frontal view. (B) PET-CT sagital view. PR with allievation 
of B symptoms and blood inflammation was achieved 2 months after starting ruxolitinib. At month 6, 
the patient was slowly progressive but did refuse to stop ruxolitinib. 
CRP, c-reactive protein 
 
Fig. 3 Response after ruxolitinib. 
Illustrative patient (UPN 601001). Comparison of frontal PET-scan prior to inclusion and after 2 
months of ruxolitinib. There was a rapid improvement of constitutional symptoms after a few days 
on ruxolitinib. PET after 2 months showed metabolic PR with on a total volume reduction of tumoral 
lung lesions of 64%. 
 
Fig. 4 Waterfall plot demonstrating percent change from baseline in target tumor dimensions (best 
response, n=27). Of note, among the 32 patients evaluable for disease response, 5 had no end-of-
treatment SPD measurements by CT scan as planned by protocol because there were obvious signs 
of disease progression. 
*Persisting positive PET scan, considered as PR 
 
Fig. 5 Kaplan-Meier estimates of overall survival and progression-free survival in 32 evaluable 
patients with Hodgkin lymphoma receiving ruxolitinib. 
(A) Progression-free survival. (B) Overall survival. 
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Supplementary data: 
Mandatory dose decreases or interruptions for hematological toxicity: 
There are mandatory dose decreases or interruptions for declining platelet count or 
ANC level while on ruxolitinib therapy. Dosing must be held if platelet count decline 
below 25 x 109 /L, or if ANC falls below 0.5 x 109 /L. Patients with platelets below 50 
x 109 /L and/or ANC below 0.5 x 109 /L should be followed biweekly. 
The dose reduction strategy for platelet count is depicted in Table 1 This table takes 
into account doses that might be present after a prior dose reduction. Ruxolitinib 
dose will not be adapted to lymphocytes count. 
 
Table 1 : dose reduction strategy for low platelet count 
 
Restarting or re-instituting previous dose 
 
Dosing may be restarted following recovery of platelet count and/or ANC to 
acceptable levels. ANC level recovery to above 500/µL but less than 750/µL will allow 
dosing to be restarted at 5 mg BID. ANC level between 750 and 1000/µL may restart 
at 10 mg BID. Increase of ANC above 1000/µL will allow a further dose increase to 
the initial dosing (15 mg BID or 20 mg BID). 
 
Table 2: Restarting or increasing ruxolitinib dose after safety interruptions or dose 
reductions for low ANC count 
 
Table 3: Restarting or increasing ruxolitinib dose after safety interruptions or dose 
reductions for low platelet count 
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Rules for permanent discontinuation  
If the study drug is interrupted for any reason for more than 4 weeks, dosing may not 
be restarted. Study drug must be permanently discontinued if the lowest allowed 
dose (5 mg BID, or 5 mg QD with concomitant CYP3A4 inhibitor) is not tolerated due 
to the following: platelet count cannot be maintained > 25 x 109 /L, ANC cannot be 
maintained > 0.5 x 109 /L. Study drug must also be permanently discontinued due to 
the following: > grade 3 clinical event after re-challenge with the drug. Exceptions 
NOT requiring study withdrawal are fatigue, insomnia, obesity, constitutional 
symptoms (disabling but not life-threatening), salivary gland changes, arthritis, and 
joint effusion. 
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PDGF-BB	concentration	in	patients	with	(n=8)	or	without	(n=17)	pruritus	before	treatment	(-)	and	
after	one	cycle	of	ruxolitinib	(+).		
